Sugi Predict

Sugi Predict / Targets / PLA2G2E

PLA2G2E

Group IIE secretory phospholipase A2 · Q9NZK7 · PLA2G2E on Sugi Atlas →

2,445 patent compounds predicted against PLA2G2E, 1,546 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL5157654 SCHEMBL5157654 1.00 9/20
SCHEMBL6309980 SCHEMBL6309980 0.60 9/20
SCHEMBL5530394 SCHEMBL5530394 1.00 8/20
SCHEMBL5790532 SCHEMBL5790532 1.00 8/20
Water Water (SCHEMBL5159364) 0.84 8/20
Water Water (SCHEMBL5159370) 0.84 8/20
SCHEMBL5788255 SCHEMBL5788255 0.81 8/20
SCHEMBL5763594 SCHEMBL5763594 0.61 8/20
SCHEMBL818585 SCHEMBL818585 0.85 7/20
SCHEMBL6288180 SCHEMBL6288180 0.73 7/20
SCHEMBL5160697 SCHEMBL5160697 0.65 7/20
SCHEMBL5766265 SCHEMBL5766265 0.63 7/20
SCHEMBL6283147 SCHEMBL6283147 0.61 7/20
SCHEMBL5157692 SCHEMBL5157692 0.61 7/20
SCHEMBL6285078 SCHEMBL6285078 0.60 7/20
SCHEMBL5764980 SCHEMBL5764980 0.58 7/20
SCHEMBL5762119 SCHEMBL5762119 0.58 7/20
SCHEMBL5160140 SCHEMBL5160140 0.54 7/20
SCHEMBL6312131 SCHEMBL6312131 0.54 7/20
SCHEMBL5763443 SCHEMBL5763443 0.52 7/20

Clinical trials — most relevant to PLA2G2E by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparative Assessment of Preoperative Versus Postoperative Submucosal Dexamethasone on Postoperative Complications Following Surgical Extraction of Mandibular Third Molar: Randomized Controlled Trial PHASE4NOT_YET_RECRUITING
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis PHASE3COMPLETED
Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial PHASE3COMPLETED
European Celecoxib Trial in Primary Breast Cancer PHASE3COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes PHASE3UNKNOWN
Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy PHASE3COMPLETED
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM PHASE3COMPLETED
Omega-3 Oil Use in COVID-19 Patients in Qatar PHASE3UNKNOWN
Effectiveness of Vitamin D in Primary Dysmenorrhoea PHASE3COMPLETED
Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy PHASE3COMPLETED
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study PHASE2/PHASE3RECRUITING
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Lovaza's Effect on the Activation of Platelets PHASE2COMPLETED
Assessment of Coronary Plaque Composition PHASE1COMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke nanCOMPLETED
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes nanCOMPLETED
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients nanCOMPLETED
Mucomyst for Hepatitis C nanSUSPENDED
Role of PLA2G1B During HIV Infection nanUNKNOWN
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy nanCOMPLETED
Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis. nanCOMPLETED
PET Imaging of DHA Metabolism nanCOMPLETED
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates nanRECRUITING
An Outcome Analysis of Primary Membranous Nephropathy nanRECRUITING
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer nanCOMPLETED
Local Anaesthetic and Steroid in the Ureter nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PLA2G2E binder may also engage these)

ProteinNameSimilarity
Q9QUL3 — 1.000 Q9QUL3 →
Q9WVF6 — 0.996 Q9WVF6 →
PLA2G2D Group IID secretory phospholipase A2 0.995 landscape →
Q71QE8 — 0.994 Q71QE8 →
Q2YHJ7 — 0.993 Q2YHJ7 →
Q90W39 — 0.992 Q90W39 →
Q6EER4 — 0.992 Q6EER4 →
P97391 — 0.991 P97391 →
P24027 — 0.991 P24027 →
P47711 — 0.991 P47711 →
Q2YHJ2 — 0.990 Q2YHJ2 →
Q6EER6 — 0.990 Q6EER6 →
Q8JIY9 — 0.989 Q8JIY9 →
P20474 — 0.989 P20474 →
P24293 — 0.989 P24293 →
Q1ZY03 — 0.989 Q1ZY03 →
Q56JZ2 — 0.989 Q56JZ2 →
P59071 — 0.989 P59071 →
P86974 — 0.988 P86974 →
P0DJN7 — 0.988 P0DJN7 →
O42187 — 0.988 O42187 →
A8CG90 — 0.988 A8CG90 →
Q6H3C5 — 0.987 Q6H3C5 →
P48650 — 0.987 P48650 →
P62023 — 0.987 P62023 →
P0CAS5 — 0.987 P0CAS5 →
Q805A2 — 0.987 Q805A2 →
P0CAS6 — 0.987 P0CAS6 →
Q6EER3 — 0.987 Q6EER3 →
Q6EER5 — 0.987 Q6EER5 →